RxDoctor Payments Data

Harry Fuentes Bayne, MD

Medical Oncology · Rochester, MNNPI 1194131995

Payments from drug & device makers

$483in general payments, 2019–2025

Across 1 payment — averaging $482.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$483

What the payments were for

  • Grants$483100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk1$483

How this compares

$483 in reported general payments places this provider in the 25th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,065,524
Medicare patients
445
Services billed
65,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$16,033
Ondansetron Hcl55$869
Prochlorperazine Maleate51$487
Olanzapine38$482
Oxycodone Hcl15$297
Dexamethasone46$293
Prednisone14$89

Paid to pharmacies, not to this prescriber.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →